Demographic and baseline characteristics of all patients randomised to treatment with salmeterol (SAL), fluticasone propionate (FP), salmeterol/fluticasone propionate combination (SFC) or placebo according to degree of adherence
| SAL (N = 1521) | FP (N = 1534) | SFC (N = 1533) | Placebo (N = 1524) | |||||
| Poor | Good | Poor | Good | Poor | Good | Poor | Good | |
| N (%) | 294 (19.3) | 1227 (80.7) | 303 (19.8) | 1231 (80.2) | 309 (20.2) | 1224 (79.8) | 326 (21.4) | 1198 (78.6) |
| Age (years) | 66.4 | 64.8 | 66.0 | 64.8 | 65.6 | 64.9 | 65.6 | 64.9 |
| Male gender (%) | 73 | 77 | 76 | 75 | 74 | 75 | 73 | 77 |
| BMI (kg/m2) | 25.5 | 25.3 | 25.4 | 25.3 | 25.2 | 25.4 | 25.3 | 25.5 |
| Current smoker (%) | 44 | 43 | 44 | 43 | 44 | 43 | 48 | 42 |
| Postbronchodilator | ||||||||
| FEV1 (ml) | 1141 | 1227 | 1217 | 1233 | 1212 | 1239 | 1188 | 1240 |
| FEV1 (% predicted) | 42.4 | 44.1 | 44.2 | 44.7 | 44.3 | 44.8 | 43.6 | 44.4 |
| MRC dyspnoea score 4 and 5 (%) | 27 | 17 | 23 | 17 | 22 | 17 | 20 | 18 |
| SGRQ total score | 52.1 | 49.3 | 49.4 | 49.6 | 50.1 | 48.5 | 50.8 | 48.5 |
| Treatment with ICS in year before study (%)* | 40 | 47 | 45 | 48 | 44 | 50 | 56 | 52 |
| >1 moderate or severe exacerbation in year before study (%)* | 33 | 33 | 33 | 32 | 32 | 32 | 36 | 31 |
Data are mean values unless otherwise indicated.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; MRC, Medical Research Council; SGRQ, St George Respiratory Questionnaire
*Self-reported in the 12 months before screening.